Notice Number: NOT-CA-15-037
Key Dates
Release Date: October 21, 2015
Estimated Publication Date of Announcement: December 2015
First Estimated Application Due Date: February 2016
Earliest Estimated Award Date: November 2016
Earliest Estimated Start Date: December 2016
Issued by
National Cancer Institute (NCI)
Purpose
The National Cancer Institute (NCI) intends to reissue a Funding Opportunity Announcement (FOA) to support exploratory research focused on the early-stage development research for highly innovative molecular or cellular analysis technologies relevant to basic and clinical cancer research.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
The FOA is expected to be published in Fall 2015 with an expected application due date in Winter 2016.
This FOA will utilize the R21 activity code. Details of the planned FOA are provided below.
This Notice encourages investigators with expertise and insights into unmet needs for molecular and cellular analysis capabilities relevant to cancer research to consider applying for this reissued FOA with applications to develop new technologies that may provide those capabilities. The IMAT program is aimed at the early-stage development and integration of novel and emerging technologies that ultimately support cancer research, diagnosis, and treatment. These technology-focused FOAs may support research including, but not limited to, novel instrumentation, materials, devices, chemical methodologies and analysis/controls tools (e.g., computer software). The IMAT program supports such work through 4 closely related FOAs; two phases of support (R21 and R33) for each of two unique thematic areas (molecular/cellular analysis technologies and biospecimen science technologies).
The emphasis of this FOA is on supporting the development of novel molecular and cellular analysis capabilities with a high degree of technical innovation and with the potential to significantly accelerate and/or transform investigations exploring or targeting the molecular and cellular basis of cancer. If successful, these technologies should accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, and/or cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on innovative molecular and/or cellular characterizations of cancer.
Applications must include quantitative milestones for each specific aim as a way of determining during the project, and at its completion, whether an applicant has successfully met the proposed functionality described in the specific aims. Milestones should be clearly stated as numerical (i.e., quantifiable) specifications for relevant measures/properties, including the description for how each milestone will be ascertained with the degree of acceptable confidence in those measures. Milestones should further serve to benchmark the performance level of the technology. Please note that a timeline of tasks to be accomplished is not acceptable as a listing of milestones for the purposes of these solicitations.
General attributes applicable to this FOA:
Note on Other Related Programs: Researchers focusing on applying new bioinformatics or statistical techniques as the primary focus of their applications, or where the technical innovation is focused on developing novel software or informatics approaches, should consider one of the Informatics Technologies for Cancer Research (ITCR) opportunities.
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.
Inquiries
Please direct all inquiries to:
Tony Dickherber, Ph.D.
National Cancer Institute (NCI)
Telephone: 301-547-9980
Email: dickherberaj@mail.nih.gov